Denmark-based biopharmaceutical company Orphazyme closed its series A round of funding on the 7th of September, raising €14m ($19.2m). The round was funded by Novo Ventures, the corporate venturing unit of Denmark-based healthcare company Novo, and venture capital firms Aescap Ventures and Sunstone Capital. Novo A/S acts as the holding company for its parent corporation, the Novo Group.
Novo Seeds, which acts as an early entry unit for the Novo Group as a whole, provided the initial seed funding for…
